



US – Russia Innovation Seminar
Washington, DC
November 24, 2008



Boston BioCom Summary

- ◆ Life science commercial development company
 - Primary focus: drugs and other therapeutic products
- ◆ Co-founded with Partners Healthcare and funded by Pfizer
- ◆ Unique, long standing relationship with Russian scientific and clinical and industrial network
- ◆ Selected products and technologies thoroughly vetted and validated by BioCom industry partners
- ◆ BioCom provides funding and initial management of programs through development milestones
- ◆ Diversified commercialization model through formation of subsidiary companies, licensing or technology sales



Boston BioCom Genesis

- ◆ **Legacy of Soviet and Western government investment in Russia**
 - Billions spent on bioweapons research and its aftermath
- ◆ **U.S. State Department engagement of CIMIT-Russia program (2003-2006)**
 - Many institutions, scores of scientists
 - Hundreds of technologies uncovered
 - Dozens of technologies vetted
 - Attractive opportunities without commercial outlets
- ◆ **Boston BioCom created to address this opportunity**



Premier Industry Partners




Six other affiliates of Harvard Medical School





Unique Blend of Assets

- Synergistic nexus of:**
- ◆ **A robust reservoir of biomedical breakthroughs from unique innovation networks addressing huge unmet needs**
 - ◆ **World-class research, validation and development resources**
 - ◆ **A proven team of commercialization experts**





Executive Management Team

Frank A. Dinucci: President and CEO

- ◆ CEO CT Innovations venture fund
- ◆ Founding Partner, Forest Street Capital
- ◆ Head, Investment Banking, Conning & Co.
- ◆ Investment Banker, Merrill Lynch
- ◆ Institutional Investment, Aetna

Hamed Abdou: VP Operations

- ◆ SVP Mfg. & Supply Chain, OSI Pharm.
- ◆ Senior Exec. Committee, Eyetech
- ◆ Pres. Worldwide Tech Ops., BMS
- ◆ Corp. Exec. Committee, BMS

James A. Bento, Treasurer & Controller

- ◆ Managing Director, e-Business Solutions
- ◆ CFO, Trumpf Industrial Lasers
- ◆ COO & CFO, Flexwatt Corporation
- ◆ CFO, Kloss Video Corporation

Timothy Brauns: VP Strategic Planning

- ◆ Senior Advisor Business Development, CIMIT Russia Team
- ◆ Associate Director, CIMIT International Program, MGH
- ◆ Business development consultant with US companies and venture funds

Alexey Eliseev: VP Business Development

- ◆ PhD Moscow State, MBA MIT
- ◆ Co-Founder several biotech companies
- ◆ CTO Alantox Pharm., Pres. US Division
- ◆ Numerous relationships in Russia
- ◆ CIMIT team

Jeffrey Gelfand: CSO

- ◆ Prof. Harvard Medical School and MGH Clinician
- ◆ Prof. Tufts Medical School
- ◆ Chair, Dept. of Medicine, Tufts University
- ◆ Physician-In-Chief, NE Medical Center

Alex Nivorozhkin: VP Technologies

- ◆ PhD Rostov U., Russia
- ◆ Researcher, Harvard & universities in Russia and Europe
- ◆ Head Medicinal Chemistry, Inotek
- ◆ Medicinal Chemist, Epix Medical
- ◆ Co-Inventor of drug candidates in clinical trials

Jan Andrew Buck: Strategic Advisor

- ◆ Biotech CEO
- ◆ Serial biotech start-ups and commercializations
- ◆ SRI (Stanford Research Institute)
- ◆ Arthur D. Little
- ◆ VP Corp. Dev., Bristol-Myers, Squibb



Company Board of Directors

Frank Dinucci

President and CEO, Boston BioCom

Frederick Frank

Vice Chairman, Lehman Brothers

Barbara Dalton

Vice President Venture Capital & Worldwide Business Development, Pfizer

Jay Pieper

Vice President Corporate Development and Treasury, Partners HealthCare

Charles Sanders

*Former Chairman and CEO, Glaxo Inc.
Former Executive Director, Massachusetts General Hospital*



Status of Opportunity Development

- ◆ **Established unique innovation networks**
 - Russian scientists, institutes and companies
 - Partners research institutions (MGH and BWH)
 - CIMIT network (HMS-affiliated institutions, BU, MIT, etc.)
 - Unprecedented access to these networks
- ◆ **Completed initial evaluation**
 - Reviewed hundreds of presentations
 - Vetted dozens of technologies in more detail
 - Boston BioCom review of about 40 technologies
 - Four technology platforms prioritized for development
- ◆ **Ongoing review of Russian and Partners/CIMIT opportunities**



Products and Technologies

		Therapeutic Area		
		Oncology	Infectious Diseases	CNS Diseases
Technology	Protein and peptide based drugs	New generation of therapeutic antibodies	Bacteriocins	
	Small molecule drugs			Anti-Alzheimer and schizophrenia drugs
	Medical Devices		Laser vaccine adjuvant	



Mechanisms of US-Russian Cooperation

- ◆ **Collaboration is key**
 - Joint research in Russian companies & institutes and Partners/Harvard laboratories
- ◆ **New intellectual property created jointly**
 - Historical Russian developments often are IP-problematic
 - New patents are created jointly and rights are co-owned by Russian and US collaborators
- ◆ **Parallel product development for Russian and global markets**
 - Partnerships with Russian pharmaceutical companies



Future Directions

- ◆ **Formation of independent spin-off companies based on individual projects**
- ◆ **Evaluation and launch of new projects**
- ◆ **Cooperation with Russian innovation investment network (venture funds, Rosnano, etc.)**
- ◆ **Collaboration with Russian partners in commercialization of existing products in the global market**